Video

Dr. Navai on Treatment Options in Relapsed/Refractory Sarcoma

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

Patients with relapsed/refractory sarcoma have very limited treatment options, says Navai. Despite all of the trials that have been done over the past 40 years in osteosarcoma, there has been no improvement in survival. Although patients have access to chemotherapy and emerging targeted therapies, they have shown limited efficacy, she adds.

HER2 is expressed in some sarcomas and has been explored as a potential target, but it is not gene-amplified, as it is in breast cancer. The levels of surface expression are much lower, and a result, HER2-targeted antibodies have not shown any activity in this setting. CAR T-cell therapies, however, have the ability to detect HER2 mutations at significantly lower levels, concludes Navai.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD